Summary.-A reduced response of a tumour to chemotherapy may be due to the host's drug metabolism. To test this hypothesis, we measured the metabolism of a model drug, para-aminosalicylate (PAS). Volunteers and cancer patients ingested a single oral dose (2 g) of PAS and we measured the plasma disappearance curve of the drug and its metabolite. In 7 patients suffering from lymphosarcoma, acute or chronic leukaemia and resistant to cancer chemotherapy, we observed low plasma PAS concentrations, an increase in PAS acetylation and an increased number (and a higher frequency) of abnormal liver-function tests. In 14 patients with malignant blood disease, yet responding well to chemotherapy, the metabolism of PAS is similar to that of healthy controls of the same age and sex. The plasma half-life of PAS is similar in sensitive and resistant patients, but slightly longer than in volunteers. Finally, in urine collected 120 min after drug administration, we observed the same results as in plasma. In conclusion, cancer patients resistant to chemotherapy do not metabolize the model drug PAS as volunteers or sensitive patients do, and this might be relevant to the terminal stage of the disease.
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CLINICAL resistance to cancer chemotherapy still constitutes a major problem in the use of therapeutic agents (Lane, 1974) . Inadequate response to treatment might be explained by, among many mechanisms, altered kinetics of antineoplastic drugs (Connors, 1974; Dedrick et al., 1975; Lavigne, 1976) .
On the other hand, many studies have shown the non-specific influence of malignant diseases on drug metabolism. Indeed, the presence of cancer modifies the pharmacokinetics of several drugs with or without antineoplastic properties. Moreover, it is known that the activity of the hepatic enzymes responsible for drug oxidation, reduction, hydrolysis (Phase I drug reactions) and conjugation (Phase II drug reactions) are unspecifically influenced by, for example, a disease or a drug metabolism inducer or inhibitor (Bousquet, 1970) .
Consequently, we decided to measure the in vivo metabolism of a model drug, para-aminosalicylate (PAS), in patients suffering from malignant blood disease and sensitive or resistant to cancer chemotherapy. The purpose of the present study was to investigate the possible relationship between the degree of resistance to cancer chemotherapy and the pharmacokinetics of our model drug, with reference to some tests of liver function.
MATERIALS AND METHODS
Control and test subjects. Drug administration.-Volunteers and patients were asked to abstain from foods and drugs for 12 h preceding drug administration. They ingested, with 100 ml of water, 4 gelatin capsules, each containing 500 mg of sodium para-aminosalicylate PAS). A catheter (" Butterfly-21 ") was inserted in a vein of the forearm, and blood samples (5 ml) were taken at 10, 30, 60 and 120 min after PAS administration (plus one sample taken before PAS). Between each sampling, 0 3 ml of heparin (1000 u/ml) was introduced in the catheter to prevent blood coagulation. Urine was collected at the end of the test.
Assay for PAS and APAS.-PAS was measured in plasma and urine according to the method described by Bratton and Marshall (1939) 
RESULTS
The plasma disappearance curves of unchanged para-aminosalicylate (PAS) after a single oral dose of PAS are presented in Fig. 1 In urine collected at 120 min after drug administration, there is no significant difference for PAS and APAS between Groups I and II (Table I) . But (Chabner et al., 1975) .
We decided to measure p-aminosalicylate (PAS) metabolism for two reasons. First, the presence of cancer modifies the pharmacokinetics of many drugs, antineoplastic (Kato et al., 1968b; Bartosek et al., 1973; Benjamin, 1974; Bartosek et al., 1975; Lavigne et al., 1975; Donelli et al., 1976) as well as other (Kato, Takanaka and Oshima, 1968a; Rosso, Dolfini and Donelli, 1968; Franchi and Rosso, 1969; Rosso et al., 1971; Basu, Parke and -1-583 iiO Williams, 1974a; Sharma and Garb, 1974; Beck, Mandel and Fabro, 1975; Nadeau and Marchand, 1975; Marchand and Nadeau, 1976) . Second, some metabolic properties of PAS (Way et al., 1948; Wan et al., 1974) such as short plasma half-life, predominantly renal excretion and the absence of side-effects at the dose used (Weinstein, 1975) make it an interesting model drug.
In healthy volunteers (Group I) the plasma peak concentration of sodium PAS (Fig. 1) and the plasma half-life (Fig. 2) are comparable with reported values (Way et al., 1948; Lavigne and Marchand, 1973; Wan et al., 1974; Weinstein, 1975) . The PAS concentrations ( Fig. 1) (Nadeau and Marchand, 1975 ) and in L1210 leukaemic mice (Marchand and Nadeau, 1976) . Many factors could be responsible for impaired drug absorption, such as decreased mucosal blood flow to the intestine and slowing in gastric emptying (Levine, 1970) , necrosis and leukaemic infiltration of the gastrointestinal tract (Matis, 1974) , and occlusion of the small intestine (Gardais, Francois and Ronceray, 1976) .
The slightly prolonged plasma half-life of PAS in patients suffering from malignant blood disease is not surprising (Fig. 2) . The disappearance rate of carisoprodol (Kato et al., 1968a) , pentobarbital (Rosso et al., 1971; Beck et al., 1975) , adriamycin (Benjamin, 1974) , sulphacetamide (Nadeau and Marchand, 1975) and cyclophosphamide (Donelli et al., 1976) from the plasma of cancer animals or patients was slower than that of controls. For these drugs, prolonged plasma half-life was usually explained by decreased drug-metabolizing activity in liver enzymes.
In the present experiments, we observed a significant increase of PAS acetylation (Fig. 3) in Group III patients. N-acetyl-p-aminosalicylic acid (APAS) is the principal metabolite of PAS (Way et al., 1948; Wan et al., 1974) and this conjugation of PAS with acetyl radical leads to an inactive product, as happens in most Phase II drug reactions (Bousquet, 1970) . The high percentage of APAS might therefore be correlated with the low plasma level of unchanged active PAS in the plasma of Group III (Fig. 1) . We may argue that the enhanced catabolism of PAS, although unexplained, is as noxious to our Group III patients as the known decreased hepatic activation of some antineoplastic drugs is to tumourbearing animals (Kato et al., 1 968b; Bartosek et al., 1975; Donelli et al., 1976) . It is known that antineoplastic agents are activated into cytotoxic metabolites or inactivated into degradation products mainly by the Phase I drug reactions (oxidation, reduction, hydrolysis). However, adrenocortical steroids are conjugated with sulphate or with glucuronic acid, and 6-mercaptopurine undergoes a methylation (conjugation) to give 6-MMP (Calabresi and Parks, 1975; Chabner et al., 1975) .
In urine collected at 120 min following drug administration (Table I) (1948) , for healthy volunteers. Impaired excretion of PAS in Group III is possible, but is difficult to assess, because the 5% of the dose excreted after 120 min may be explained by the low plasma concentrations of PAS (Fig. 1) compared with volunteers. The slightly prolonged plasma half-life of PAS cannot explain a slower renal clearance, because Group II, who also have a slightly prolonged halflife, excrete PAS as well as volunteers do.
We must stress that our subjects were volunteers or patients of either sex, young and old. As far as the curves of plasma disappearance of PAS, acetylation and renal excretion are concerned, age and sex did not seem to have any effect, contrary to what is reported in the literature for many drugs (Bousquet, 1970; Triggs and Nation, 1975) . But, in agreement with the study of Kampmann, Sinding and Jorgensen (1975) , we did not find any effect of age on liver functions. In Group II (Table II) , only 2 sensitive patients had 2 or 3 moderately abnormal liver functions, and 5 of these patients have only slightly low total serum proteins (5a3-5*7%o). In this group, one patient suffering from lymphosarcoma had an elevated level of alkaline phosphatase, an enzyme whose elevation correlates well with this disease (Belliveau, Wiernik and Abt, 1974) . Finally, the higher frequency of abnormal liver function in Group III must be pointed out. The far-advanced malignant disease is probably more responsible than the chemotherapy for the impaired liver functions. Such findings were reported earlier in patients with advanced non-hepatic cancer (Basu, Raven and Williams, 1974b) and it is also known that hepatic failure is a cause of death in leukaemia (Chang et al., 1976) . The fact that 3 out of 4 resistant patients have low serum albumin is interesting because, as mentioned by Wilkinson and Schenker (1975) , depressed serum albumin level and/or prolonged prothrombin time have provided the only significant correlations between biochemical assessment of liver function and drug disposition. Hypoalbuminaemia may account for a possible diminution of albumin binding of drugs, and the smaller the extent of albumin binding, the more drug will be available for hepatic biotransformation (Koch-Weser and Sellers, 1976) . The significant increase in PAS acetylation (Group III) might in part be so explained. It is also important to note that 2/4 resistant patients had elevated creatinine levels. But even if renal complications may occur in leukaemia and lymphomas (Frei et al., 1963) , a definite correlation with PAS excretion cannot be made.
To summarize our results, malignant blood diseases did not seem greatly to influence PAS metabolism in sensitive patients. However, in cancer patients resistant to chemotherapy, we think that changes in PAS absorption, fate and excretion might reflect, by analogy, changes in antineoplastic drug metabolism. Of course, in these patients it may be hard to dissociate resistance to chemotherapy from the advanced stage of the disease. As mentioned earlier, these patients died shortly (30-90 days) after our study and moreover, as demonstrated in tumour-bearing animals (Kato et al., 1968a, b; Rosso et al., 1968; Franchi and Rosso, 1969; Rosso et al., 1971; Basu et at., 1974a; Beck et al., 1975; Lavigne et al., 1975 ) drug metabolism and action were progressively modified as a function of tumour growth.
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